HUP0105027A2 - N-Heterociklusos vegyületek karbonsavszármazékai és karbonsav-izoszterei és alkalmazásuk - Google Patents

N-Heterociklusos vegyületek karbonsavszármazékai és karbonsav-izoszterei és alkalmazásuk

Info

Publication number
HUP0105027A2
HUP0105027A2 HU0105027A HUP0105027A HUP0105027A2 HU P0105027 A2 HUP0105027 A2 HU P0105027A2 HU 0105027 A HU0105027 A HU 0105027A HU P0105027 A HUP0105027 A HU P0105027A HU P0105027 A2 HUP0105027 A2 HU P0105027A2
Authority
HU
Hungary
Prior art keywords
treatment
carboxylic acid
heterocyclic compounds
acid isosteres
carboxylic
Prior art date
Application number
HU0105027A
Other languages
English (en)
Inventor
Gregory S. Hamilton
Mark H. Norman
Yong-Qian Wu
Original Assignee
Amgen, Inc.
Gpi Nil Holdings, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen, Inc., Gpi Nil Holdings, Inc. filed Critical Amgen, Inc.
Publication of HUP0105027A2 publication Critical patent/HUP0105027A2/hu
Publication of HUP0105027A3 publication Critical patent/HUP0105027A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

A találmány N-heterociklusos vegyületek karbonsavszármazékaira éskarbonsav-izosztereire, ezek előállítására, gyógyászati kompozíciókbantörténő alkalmazására, továbbá neurológiai rendellenességek kezelésétés/vagy megelőzését; továbbá hajhullás kezelését és a hajnövekedésserkentését; továbbá látási rendellenességek kezelését és/vagy a látásjavítását; továbbá memóriaromlás kezelését és/vagy a memóriateljesítményének javítását; továbbá állatoknál szőrzet vesztésénekkezelését és/vagy megelőzését célzó használatára és előállításáravonatkozik. A találmány tárgyához tartoznak továbbá az (I) általánosképletű vegyületek, melyek Hutington-féle betegség kezelésérealkalmasak. Ó
HU0105027A 1998-12-03 1999-12-03 Carboxylic acids and carboxylic acid isosteres of n-heterocyclic compounds and their use HUP0105027A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20423798A 1998-12-03 1998-12-03
US09/453,571 US6331537B1 (en) 1998-06-03 1999-12-02 Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds

Publications (2)

Publication Number Publication Date
HUP0105027A2 true HUP0105027A2 (hu) 2002-05-29
HUP0105027A3 HUP0105027A3 (en) 2002-10-28

Family

ID=26899306

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0105027A HUP0105027A3 (en) 1998-12-03 1999-12-03 Carboxylic acids and carboxylic acid isosteres of n-heterocyclic compounds and their use

Country Status (20)

Country Link
US (2) US6331537B1 (hu)
EP (1) EP1135370B1 (hu)
KR (1) KR20010086080A (hu)
CN (1) CN1213026C (hu)
AT (1) ATE252078T1 (hu)
AU (1) AU767468B2 (hu)
BG (1) BG105643A (hu)
BR (1) BR9916461A (hu)
CA (1) CA2353460C (hu)
CZ (1) CZ20011971A3 (hu)
DE (1) DE69912151T2 (hu)
EA (1) EA003926B1 (hu)
HU (1) HUP0105027A3 (hu)
IL (1) IL143392A0 (hu)
MX (1) MXPA01005549A (hu)
NO (1) NO318909B1 (hu)
NZ (1) NZ511673A (hu)
PL (1) PL348715A1 (hu)
SK (1) SK7442001A3 (hu)
WO (1) WO2000032588A2 (hu)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US20010049381A1 (en) * 1997-06-04 2001-12-06 Gpl Nil Holdings, Inc., Pyrrolidine derivative hair growth compositions and uses
US6274602B1 (en) * 1998-06-03 2001-08-14 Gpi Nil Holdings, Inc. Heterocyclic thioester and ketone hair growth compositions and uses
JP2001516767A (ja) * 1997-09-24 2001-10-02 アムジエン・インコーポレーテツド 感覚神経向性化合物を使用する難聴の予防及び治療法
BR0012327A (pt) 1999-07-09 2002-07-02 Ortho Mcneil Pharm Inc Pirrolidinas e piperidinas neurotróficas, e composições e métodos relacionados
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
US6809093B2 (en) 2000-10-17 2004-10-26 H. Lee Moffitt Cancer & Research Institute, Inc. 2-substituted heterocyclic compounds
US6608196B2 (en) 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
ES2314100T3 (es) 2001-05-03 2009-03-16 Monsanto Technology Llc Derivados de piruvato.
US20030203890A1 (en) * 2001-05-29 2003-10-30 Steiner Joseph P. Method for treating nerve injury caused as a result of surgery
AUPR879201A0 (en) * 2001-11-09 2001-12-06 Cochlear Limited Subthreshold stimulation of a cochlea
US20050171579A1 (en) * 2001-11-09 2005-08-04 Claudia Tasche Stimulating device
US20100030130A1 (en) * 2001-11-09 2010-02-04 Cochlear Limited Pharmaceutical intervention for modulation of neural plasticity
US20100030301A1 (en) * 2001-11-09 2010-02-04 Cochlear Limited Electrical stimulation for modulation of neural plasticity
US7521584B2 (en) * 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
WO2004011423A2 (en) 2002-07-29 2004-02-05 Hawaii Biotech, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US7723327B2 (en) 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US7345091B2 (en) 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US7320997B2 (en) 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US7763649B2 (en) 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
AU2003259846A1 (en) * 2002-08-16 2004-03-03 The General Hospital Corporation Non-invasive functional imaging of peripheral nervous system activation in humans and animals
KR20050047132A (ko) * 2002-10-03 2005-05-19 버텍스 파마슈티칼스 인코포레이티드 신경계 질환 치료용 피페라진 및 피페리딘 유도체
EP1750723A1 (en) * 2004-04-14 2007-02-14 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US8965520B2 (en) 2004-06-15 2015-02-24 Cochlear Limited Automatic determination of the threshold of an evoked neural response
US20060116423A1 (en) * 2004-10-18 2006-06-01 Dash Pramod K Methods and compositions for treatment of central nervous system injury with isothiocyanates
EP1833787A2 (en) * 2004-11-30 2007-09-19 Plexxikon, Inc. Indole derivatives for use as ppar active compounds
ZA200708179B (en) 2005-04-22 2009-12-30 Alantos Pharmaceuticals Holding Inc Dipeptidyl peptidase-IV inhibitors
WO2006138187A1 (en) * 2005-06-13 2006-12-28 Yong-Qian Wu Enhanced tissue penetration prodrugs
CA2621474A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. 1,3-disubstituted indole derivatives for use as ppar modulators
DE102005050377A1 (de) * 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
CN105541769A (zh) 2007-06-29 2016-05-04 奥克塞拉有限公司 用于治疗眼科疾病和紊乱的炔基苯基衍生化合物
CA2701116C (en) 2007-10-05 2013-02-05 Acucela Inc. Alkoxy compounds for disease treatment
US8076516B2 (en) 2007-11-01 2011-12-13 Acucela, Inc. Amine derivative compounds for treating ophthalmic diseases and disorders
CA2721944C (en) 2008-04-24 2016-06-07 F2G Ltd Pyrrole antifungal agents
WO2010013240A1 (en) 2008-07-31 2010-02-04 Dekel Pharmaceuticals Ltd. Compositions and methods for treating inflammatory disorders
NZ592993A (en) 2008-10-22 2013-02-22 Acucela Inc Compounds for treating ophthalmic diseases and disorders
US20100317711A1 (en) * 2008-12-17 2010-12-16 Gliamed, Inc. Stem-like cells and method for reprogramming adult mammalian somatic cells
WO2011003103A2 (en) * 2009-07-02 2011-01-06 Acucela, Inc. Pharmacology of visual cycle modulators
US9981018B2 (en) * 2010-06-08 2018-05-29 The Cleveland Clinic Foundation Compositions and methods for modulating toll-like receptor 2 activation
US9447078B2 (en) 2012-01-20 2016-09-20 Acucela Inc. Substituted heterocyclic compounds for disease treatment
US9505728B2 (en) 2012-03-09 2016-11-29 Inception 2, Inc. Triazolone compounds and uses thereof
MX2015007433A (es) 2012-12-20 2015-12-07 Inception 2 Inc Compuestos de triazolona y usos de los mismos.
WO2015035059A1 (en) 2013-09-06 2015-03-12 Inception 2, Inc. Triazolone compounds and uses thereof
US20150202186A1 (en) * 2014-01-23 2015-07-23 Sova Pharmaceuticals, Inc. CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN
CA2982660C (en) 2014-11-21 2023-01-24 F2G Limited 2-(1,5-dimethyl-3-phenyl-1h-pyrrol-2-yl)-n-(4-(4-(5-fluoropyrimidin-2-yl)piperazine-1-yl)phenyl)-2-oxoacetamide and derivatives thereof for use as antifungal agents
MX2018001843A (es) * 2015-08-13 2018-05-16 River Town Therapeutics Inc Composiciones y metodos para tratar alopecia.
US10285977B2 (en) * 2015-08-13 2019-05-14 David Weinstein Consulting, Inc. Compositions and methods for treating alopecia
US20170266157A1 (en) * 2016-03-21 2017-09-21 David Weinstein Methods for wound healing and scar prevention
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
US10709686B2 (en) * 2018-03-20 2020-07-14 David Weinstein Consulting, Inc. Methods for treating pulmonary fibrosis
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA794723B (en) 1978-09-11 1980-08-27 Univ Miami Anti-hypertensive agents
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
IT1148775B (it) 1980-02-29 1986-12-03 Attilio Pronzati Bastoncini da sci dotati di rotelle intercambiabili
US4734420A (en) 1980-03-05 1988-03-29 University Of Miami Anti-hypertensive agents
US4692458A (en) 1980-03-05 1987-09-08 University Of Miami Anti-hypertensive agents
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
EP0048159A3 (en) 1980-09-17 1982-05-12 University Of Miami Novel carboxyalkyl peptides and thioethers and ethers of peptides as antihypertensive agents
EP0050800B2 (en) 1980-10-23 1995-06-07 Schering Corporation Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them
US5348944A (en) 1980-10-23 1994-09-20 Schering Corporation Carboxyalkyl dipeptides
ZA817261B (en) 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
US4766110A (en) * 1981-08-21 1988-08-23 Ryan James W Novel complex amido and imido derivatives of carboxyalkyl peptides
ZA826022B (en) 1981-08-21 1983-08-31 Univ Miami Novel complex amido and imido derivatives of carboxyalkyl peptides and thioethers and ethers of peptides
US4431644A (en) 1982-03-08 1984-02-14 Schering Corporation Antihypertensive agents
EP0088350B1 (en) 1982-03-08 1985-02-20 Schering Corporation Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them
EP0177581A4 (en) 1984-04-06 1987-08-10 Gail S Bazzano COMPOSITIONS FOR HAIR GROWTH.
US4595766A (en) 1984-10-26 1986-06-17 Ciba-Geigy Corporation Process for the preparation of an indoline carboxylic acid
DE3508251A1 (de) 1985-03-08 1986-09-11 Merck Patent Gmbh, 6100 Darmstadt Dipeptide
CN86101850A (zh) 1985-03-22 1987-02-04 森得克斯(美国)有限公司 N，n′-二烷基胍基二肽的制造方法与用途
US5472687A (en) 1985-07-18 1995-12-05 Proctor; Peter H. Topical pyridine N-oxides
US5714510A (en) 1985-07-18 1998-02-03 Proctor; Peter H. Topical proxyl composition and method
WO1988000040A1 (en) 1986-07-02 1988-01-14 American Health Products Corporation Topical hair growing composition and kit
US5214034A (en) 1986-09-26 1993-05-25 Mitsui Toatsu Chemicals, Incorporated Catechol derivatives, and preventive and remedial preparations for regressive disorders in the central nervous system containing the same
DE3636278A1 (de) 1986-10-24 1988-05-05 Hoechst Ag Herbizide mittel auf der basis von cyclischen (alpha)-iminocarbon-saeureaniliden sowie neue (alpha)-iminocarbonsaeureanilide und verfahren zu ihrer herstellung
IT1206078B (it) 1987-06-03 1989-04-14 Polifarma Spa Procedimento per la produzione di acido 3-indolpiruvico e suoi derivati loro uso farmaceutico
WO1989006234A1 (en) 1987-12-28 1989-07-13 Bazzano Gail S N,n-substituted amines and use thereof in hair growth promotion
US5187156A (en) 1988-03-16 1993-02-16 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
US5232923A (en) 1988-03-18 1993-08-03 Mitsui Toatsu Chemicals, Incorporated Catechol derivatives and pharmaceutical preparations containing same
US5274097A (en) 1988-04-19 1993-12-28 Bayer Aktiengesellschaft 1,3-disubstituted pyrrolidines
IL90872A0 (en) 1988-07-08 1990-02-09 Smithkline Beckman Corp Retroviral protease binding peptides
US5002962A (en) 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
US5166317A (en) 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
EP0378318A1 (en) 1989-01-11 1990-07-18 Merck & Co. Inc. Process for synthesis of FK-506 and tricarbonyl intermediates
US5359138A (en) 1989-04-15 1994-10-25 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Poststatin and related compounds or salts thereof
US5164525A (en) 1989-06-30 1992-11-17 Merck & Co., Inc. Synthetic process for fk-506 type macrolide intermediates
US5128483A (en) 1989-07-19 1992-07-07 American Cyanamid Company Dibromovinyl and acetylene-1-pyrrolidinecarboxylic acid intermediates
US5215969A (en) 1989-08-11 1993-06-01 Hahnemann University Dopaminergic neurotrophic factor for treatment of Parkinson's disease
US5703088A (en) 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
US5115098A (en) 1990-02-28 1992-05-19 President And Fellows Of Harvard College End-blocked peptides inhibiting binding capacity of gp120
JPH04211648A (ja) 1990-07-27 1992-08-03 Nippon Kayaku Co Ltd ケト酸アミド誘導体
DE4015255A1 (de) 1990-05-12 1991-11-14 Hoechst Ag Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase
US5504197A (en) 1990-06-20 1996-04-02 The Salk Institute For Biological Studies DNA encoding neurotrophic growth factors
US5192773A (en) 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
DE69030923T2 (de) 1990-08-14 1998-01-29 Kenneth M Hallam Haarwuchsmittel
GB2247456A (en) 1990-09-03 1992-03-04 Fujisawa Pharmaceutical Co Tetrahydropyrane compounds, a process for their production and a pharmaceutical composition containing the same
JPH04124198A (ja) 1990-09-12 1992-04-24 Sumitomo Pharmaceut Co Ltd 神経栄養ペプチド誘導体
EP0488258B1 (en) 1990-11-27 1996-04-17 Fuji Photo Film Co., Ltd. Propenamide derivatives, polymers, copolymers and use thereof
FR2671082B1 (fr) 1990-12-28 1993-04-16 Oreal Agent a plusieurs composants ou kit de preparation de la forme sulfo-conjuguee de composes pyrimidino- ou triazino-n-oxyde et procede de mise en óoeuvre.
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US5147877A (en) 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
US5620971A (en) 1991-05-09 1997-04-15 Vertex Pharmaceuticals Incorporated Biologically active acylated amino acid derivatives
FR2677884B1 (fr) 1991-06-20 1993-07-09 Oreal Composition pour freiner la chute des cheveux a base de pyrimidines n-oxyde trisubstitues ou leurs derives sulfoconjugues, nouveaux composes pyrimidines n-oxyde ou leurs derives sulfoconjugues.
JPH05194235A (ja) 1991-07-25 1993-08-03 Tanabe Seiyaku Co Ltd 中枢性カルシウム拮抗剤
JPH05178824A (ja) 1991-08-05 1993-07-20 Takeda Chem Ind Ltd アスパラギン誘導体およびその用途
US5604294A (en) 1991-09-05 1997-02-18 Luly; Jay R. Macrocyclic immunomodulators
CA2091194A1 (en) 1992-04-08 1993-10-09 Richard D. Connell 2-oxo-ethyl derivatives as immunosuppressants
US5342942A (en) 1992-06-09 1994-08-30 Warner-Lambert Company Pyrazoloquinazolone derivatives as neurotrophic agents
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
WO1994012474A1 (en) 1992-11-20 1994-06-09 Japan Tobacco Inc. Compound with prolyl endopeptidase inhibitor activity and pharmaceutical use thereof
US5646167A (en) 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
ATE172985T1 (de) 1993-02-09 1998-11-15 Bayer Ag Sulfonamidaminomethylenderivate als immunsuppressiva
WO1994021253A1 (en) 1993-03-17 1994-09-29 Abbott Laboratories Substituted aliphatic amine-containing macrocyclic immunomodulators
JP3599287B2 (ja) 1993-04-28 2004-12-08 三菱化学株式会社 スルホンアミド誘導体
US5319098A (en) * 1993-05-18 1994-06-07 Celgene Corporation Process for the stereoselective preparation of L-alanyl-L-proline
US5798355A (en) 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
US5846981A (en) 1993-05-28 1998-12-08 Gpi Nil Holdings Inc. Inhibitors of rotamase enzyme activity
IT1270882B (it) 1993-10-05 1997-05-13 Isagro Srl Oligopeptidi ad attivita' fungicida
US5527907A (en) 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US5612350A (en) 1993-11-30 1997-03-18 Abbott Laboratories Macrocyclic immunomodulators with novel cyclohexyl ring replacements
US5744485A (en) 1994-03-25 1998-04-28 Vertex Pharmaceuticals Incorporated Carbamates and ureas as modifiers of multi-drug resistance
US5898029A (en) 1994-04-12 1999-04-27 The John Hopkins University Direct influences on nerve growth of agents that interact with immunophilins in combination with neurotrophic factors
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
DE4425950A1 (de) 1994-07-21 1996-01-25 Bayer Ag Verwendung von Sulfonylbenzyl-substituierten Imidazolen, Imidazopyridinen und Benzimidazolen
DE69534300T2 (de) * 1994-08-18 2006-05-18 Ariad Gene Therapeutics, Inc., Cambridge Neues multimerisierendes reagenz
US5543423A (en) 1994-11-16 1996-08-06 Vertex Pharmaceuticals, Incorporated Amino acid derivatives with improved multi-drug resistance activity
US5696135A (en) 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US6291510B1 (en) * 1995-06-07 2001-09-18 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5614547A (en) 1995-06-07 1997-03-25 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5801197A (en) 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
ATE465149T1 (de) * 1996-02-28 2010-05-15 Ariad Pharma Inc Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen
US5717092A (en) 1996-03-29 1998-02-10 Vertex Pharmaceuticals Inc. Compounds with improved multi-drug resistance activity
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
KR19980018486A (ko) 1996-08-09 1998-06-05 다께다 구니오 디메틸프로판디올 화합물
US5801187A (en) * 1996-09-25 1998-09-01 Gpi-Nil Holdings, Inc. Heterocyclic esters and amides
US5786378A (en) 1996-09-25 1998-07-28 Gpi Nil Holdings, Inc. Heterocyclic thioesters
US5780484A (en) 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US5840736A (en) 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5811434A (en) 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
US5874449A (en) 1996-12-31 1999-02-23 Gpi Nil Holdings, Inc. N-linked sulfonamides of heterocyclic thioesters
US5721256A (en) 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
US5846979A (en) * 1997-02-28 1998-12-08 Gpi Nil Holdings, Inc. N-oxides of heterocyclic esters, amides, thioesters, and ketones
US5945441A (en) * 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
JP2001516767A (ja) * 1997-09-24 2001-10-02 アムジエン・インコーポレーテツド 感覚神経向性化合物を使用する難聴の予防及び治療法
DE69837564T2 (de) * 1998-06-03 2007-12-27 Gliamed, Inc. Azaheterozyklische derivate zur behandlung von haarausfall und neurologischer krankheiten
US6284779B1 (en) * 1999-02-03 2001-09-04 Schering Aktiiengesellschaft Heteroaromatic compounds

Also Published As

Publication number Publication date
CN1330634A (zh) 2002-01-09
NO20012765D0 (no) 2001-06-05
AU1841300A (en) 2000-06-19
BG105643A (en) 2002-02-28
US7153883B2 (en) 2006-12-26
CN1213026C (zh) 2005-08-03
EP1135370B1 (en) 2003-10-15
EP1135370A2 (en) 2001-09-26
US6331537B1 (en) 2001-12-18
CA2353460C (en) 2009-11-10
EA003926B1 (ru) 2003-10-30
NO318909B1 (no) 2005-05-23
CZ20011971A3 (cs) 2001-09-12
CA2353460A1 (en) 2000-06-08
DE69912151D1 (de) 2003-11-20
ATE252078T1 (de) 2003-11-15
WO2000032588A2 (en) 2000-06-08
AU767468B2 (en) 2003-11-13
NO20012765L (no) 2001-07-20
PL348715A1 (en) 2002-06-03
BR9916461A (pt) 2001-09-04
EA200100570A1 (ru) 2001-12-24
SK7442001A3 (en) 2001-12-03
HUP0105027A3 (en) 2002-10-28
WO2000032588A3 (en) 2001-02-22
DE69912151T2 (de) 2004-07-08
KR20010086080A (ko) 2001-09-07
MXPA01005549A (es) 2003-07-14
US20030186961A1 (en) 2003-10-02
IL143392A0 (en) 2002-04-21
NZ511673A (en) 2004-03-26

Similar Documents

Publication Publication Date Title
HUP0105027A2 (hu) N-Heterociklusos vegyületek karbonsavszármazékai és karbonsav-izoszterei és alkalmazásuk
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
DE69937198D1 (de) Behandlung der alzheimer-krankheit durch erhöhung des cytidin-spiegels in vivo
BG105012A (en) N-linked sulphonamides of n-heterocyclic carboxylic acids or carboxylic isosteres
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
CY1108514T1 (el) Παραγωγα 1-φαινυλαλκανεκαρβοξυλικου οξεος για τη θεραπεια νευρογενων ασθενειων
CA2396561A1 (en) Substituted oxazolidinones and their use in the field of blood coagulation
HUP0302114A2 (hu) Eritropoietin-fehérjét tartalmazó folyékony gyógyászati készítmény, eljárás előállítására és alkalmazása
RU92016244A (ru) Производные сахарина-ингибиторы протеолитических ферментов
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
HUP0100012A2 (hu) Makrolid vegyületek alkalmazása rák és a makuláns elváltozások kezelésére
ATE325610T1 (de) Xanthinderivative zur behandlung von hirnischämie
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
NO20010940L (no) TAN-1057 derivater
BR9815919A (pt) Compostos aza heterocìclicos usados para tratar distúrbios neurológicos e perda de cabelo
BG105014A (en) Ureas and carbamates of n-heterocyclic carboxylic acids and carboxylic acid isosteres
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE69621786T2 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
RU94011321A (ru) Способ профилактики и лечения заболеваний кожи
CA2290739A1 (en) New bpc peptide salts with organo-protective activity, the process for their preparation and their use in therapy
KR960000248A (ko) 골대사 질환 치료제
WO1994024279A3 (en) Agents for the prevention and treatment of huntington's disease and other neurological disorders
DE69428797T2 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees